Search Results

Explore the fascinating career journeys, groundbreaking discoveries, and impactful contributions of experts We discuss breakthrough discoveries, career paths in pharmacology and molecular biology, and how each If you’re working on exciting GPCR-related research — from structural biology to drug discovery — we’ GPCR Podcast with three major goals in mind: Share the latest scientific discoveries in the GPCR field

Discover how low-offset kinetics reshape drug efficacy. Join Terry’s Corner and master irreversible pharmacology for modern discovery programs. Home → Flash News → irreversible drugs post 1 Irreversible Drugs – Trailer Published on October 21, 2025 Category Terry's Corner Irreversible drugs change the rules of engagement. In modern discovery programs, that’s a decisive advantage (or a hidden liability) in candidate selection

Explore the kinetic principles behind persistent binding and smarter drug design. Home → Flash News → irreversible drugs post 2 Persistent binding ≠ just covalent. Published on October 24, 2025 Category Terry's Corner Why do some inhibitors act long after the drug If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More : https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding

Gabriele Kockelkoren shares: 🔬 How GPCR spatial organization shapes signaling and drug responses 🌍 the unknown is key to scientific breakthroughs A must-listen for biophysicists, pharmacologists, and drug hunters pushing the boundaries of discovery! Gabriele Kockelkoren shares:🔬 How GPCR spatial organization shapes signaling and drug responses🌍 His hunters pushing the boundaries of discovery!

Home → Flash News → terrys corner predict drug behavior Published on July 12, 2025 Category Terry's Corner Dive into the logic of drug modeling with Terry Kenakin. Learn to “extend your eyes” and predict complex drug behaviors. 🟢 Browse the full catalog (and expect

Home → Flash News → terrys corner model drug response Published on July 10, 2025 Category Terry's Corner What if a single experimental snapshot could predict an entire in vivo drug profile in a range of organs discussed. 🟢 Read the full breakdown: ✳️ https://www.ecosystem.drgpcr.com/post/what-if-you-could-predict-drug-behavior-with-just-a-snapshot

unveiled the cryo-EM structure of TAS2R14, the most promiscuous bitter taste receptor, bound to the drug 🌟 This discovery reveals an unusual dual binding mode of FFA and offers tools for site-targeted compound unveiled the cryo-EM structure of TAS2R14 , the most promiscuous bitter taste receptor, bound to the drug 🌟 This discovery reveals an unusual dual binding mode of FFA and offers tools for site-targeted compound signaling. ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a-bitter-anti-inflammatory-drug-binds-at-two-distinct-sites-of-a-human-bitter-taste-gpcr

Home → Flash News → 🚨 Exciting Opportunity for Professionals in Drug Development! GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 (including drug-drug interactions) And much more! GPCR Courses 🚨 Exciting Opportunity for Professionals in Drug Development! (including drug-drug interactions) And much more!

University" About Jesse Stillwell "Jesse Stillwell is a 3rd year graduate student with a research focus in drug His project is drug discovery focused, with particular interest in use of a novel epigenetic therapy

Home → Flash News → 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs GPCR Courses 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”!

Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development —and registration closes in 3 days! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

engaged in researching molecular mechanisms that govern human (patho-)physiology and their interplay with drugs I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets to create drugs with fewer adverse effects. I want to combine experimental approaches with data-driven discovery and adopt data science methodology

Home → Flash News → Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock 3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Published on June 2, 2025 Category GPCR Weekly News Class B GPCR drugs This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock

GPCR location within the cell can change everything: function, pharmacology, and even drug response. insights from the lab to the broader biotech world This episode is packed with knowledge for scientists, drug GPCR location within the cell can change everything: function, pharmacology, and even drug response. insights from the lab to the broader biotech world This episode is packed with knowledge for scientists, drug

is important for increasing the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development. which has important functions in hemostasis, thrombosis, inflammation, and cancer and is an important drug She has made numerous important discoveries related to the mechanisms that control PAR1 signaling and

Kenakin , a leading expert in pharmacology, as he unpacks the fascinating world of signaling bias in drug 🔹 Instead of avoiding bias, researchers can embrace it to refine drug responses. Dr. Understanding these shifts can revolutionize drug development! Terry Kenakin’s workshop offers a fresh perspective on drug discovery . Ready to explore the future of biased drug design? Let’s dive in!

research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug and drug development technology.

research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug and drug development technology.

colleagues and Alfred Gillman , co-recipient of the 1994 Nobel Prize in Physiology or Medicine for their discovery , Paul and his team focus on previously unrecognized receptors with the hopes to use these as novel drug

Support the GPCR Community — Empower the Next Generation of Discovery Your donation helps us serve the Together , we’re creating a global home for everyone passionate about GPCR research, collaboration, and discovery Together, we can accelerate GPCR discoveries and develop more effective drugs for everyone. 👉 Donate

. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug

Weekly News, featuring expert insights on target engagement, a practical framework for irreversible drugs GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs Published on October 23, 2025 Category Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “

During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen, of Molecular Biology in Cambridge, UK, where he was working on the impact of genetic variations on drug

Lauren Slosky is an Assistant Professor in the Department of Pharmacology and a member of the Medical Discovery within the University of Minnesota’s Medical School to advance research and treatment in the field of drug

into the structure, dynamics, and function of important classes of membrane proteins and prominent drug To this end, her lab uses several computational structural biology tools and rational drug design approaches

the University of Glasgow, his primary research interests are focused on the rational design of novel drugs staff supported by basic research grants investigating aspects of disease biology and the action of drugs

the study of the mechanisms involved in neurodegeneration and the characterization of neuroprotective drugs These drugs were shown to be very effective to rescue the cell death observed in a mouse model of Huntington